Effects of troglitazone on the proliferation and differentiation of HepG2 cells
- VernacularTitle:曲格列酮对肝癌HepG2细胞生长和分化的影响
- Author:
Yanming ZHOU
;
Yinghao WEN
;
Xiaoyan KANG
;
Haihua QIAN
;
Dianqi LI
;
Jiamei YANG
;
Zhengfeng YIN
- Publication Type:Journal Article
- Keywords:
Peroxisome proliferator-activated receptor γ;
Troglitazone;
Liver cancer
- From:
Chinese Journal of Digestive Surgery
2008;7(3):200-202
- CountryChina
- Language:Chinese
-
Abstract:
Objective To examine the effects of a peroxisome proliferator-activated receptor γ ligand troglitazone on the proliferation and differentiation of HepG2 cells. Methods After the pretreatment of HepG2 cells with troglitazone, MTT and flow cytometry were used to analyze the proliferation and cell cycle of HepG2 cells, respectively. Immunocytochemistry, bromocresol green dye-binding method and chemiluminessence immunosorbent assay was used to determine E-cadherin, albumin and AFP, respectively. The expression of cyclin D1 and c-myc protein were detected by Western blot. Results Troglitazone inhibited the proliferation of HepG2 cells in a concentration-dependent manner and arrested HepG2 ceils at the G0>/G1> phase. After pretreated with troglitazone, HepG2 cells showed E-cadherin expression, a decreased expression of cyclin D1 and c-myc protein, a reduction of AFP level and a dramatic increase of albumin level. Conclusions Troglitazone inhibits proliferation and induces differentiation of HepG2 cells, the mechanism of which might be attributable to the down-regulation of cyclin D1 and c-myc expression.
